Kalcipos-D 500 mg/ 800 IU chewable tablets
Each chewable tablet contains calcium carbonate equivalent to 500 mg calcium, cholecalciferol (Vitamin D3
) 800 IU (20 microgram).
Excipients: one chewable tablet contains glucose 200 mg and sucrose 1.8 mg.
For a full list of excipients, see section 6.1.
White to off white, round, engraved R152 on one side, diameter 17 mm.
Prevention and treatment of calcium and vitamin D deficiency in the elderly. Vitamin D and calcium supplement in addition to specific osteoporosis treatment of patients who are at risk of vitamin D and calcium deficiency.
Adults and elderly
One chewable tablet (500 mg/800 IU) daily. To be chewed or slowly melted in the mouth.
The amount of calcium in Kalcipos-D is less than the usually recommended daily intake.
Kalcipos-D is therefore primarily to be used by patients with need of D-vitamin substitution but with a dietary intake of calcium of 500 mg-1000 mg per day. The patients dietary intake of calcium should be estimated by the prescriber.
Dosage in hepatic impairment
No dose adjustment is required
Dosage in renal impairment
Kalcipos-D should not be used in patients with severe renal impairment (see section 4.3).
There is no relevant indication for use of Kalcipos-D chewable tablets in children or adolescents.
• Diseases and/or conditions resulting in hypercalcaemia or hypercalciuria.
• Hypervitaminosis D.
• Renal failure.
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Kalcipos-D chewable tablets should be prescribed with caution to patients suffering from sarcoidosis due to risk of increased metabolism of vitamin D into its active form. These patients should be monitored with regard to the calcium content in serum and urine.
During long-term treatment, serum calcium levels should be followed and renal function should be monitored through measurements of serum creatinine. Monitoring is especially important in elderly patients on concomitant treatment with cardiac glycosides or diuretics (see section 4.5) and in patients with a high tendency to calculus formation. In case of hypercalciuria (exceeding 300 mg (7.5 mmol)/24 hours) or signs of impaired renal function the dose should be reduced or the treatment discontinued.
Vitamin D should be used with caution in patients with impairment of renal function and the effect on calcium and phosphate levels should be monitored. The risk of soft tissue calcification should be taken into account. In patients with severe renal insufficiency, vitamin D in the form of cholecalciferol is not metabolised normally and other forms of vitamin D should be used (see section 4.3, contraindications).
Kalcipos-D chewable tablets should be used cautiously in immobilised patients with osteoporosis due to increased risk of hypercalcaemia.
The content of vitamin D (800 IU) in Kalcipos-D chewable tablets should be considered when prescribing other medicinal products containing vitamin D. Additional doses of calcium or vitamin D should be taken under close medical supervision. In such cases it is necessary to monitor serum calcium levels and urinary calcium excretion frequently.
Co-administration with tetracyclines or quinolones is usually not recommended, or must be done with precaution (see section 4.5).
Kalcipos-D chewable tablets contains glucose and 1.8 mg sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
The content of glucose may be harmful to the teeth.
Kalcipos-D chewable tablets are not intended for use in children.
Thiazide diuretics reduce the urinary excretion of calcium. Due to increased risk of hypercalcaemia, serum calcium should be regularly monitored during concomitant use of thiazide diuretics.
Concomitant use of phenytoin or barbiturates may reduce the effect of vitamin D3
since the metabolism increases.
Systemic corticosteroids reduce calcium absorption. During concomitant use, it may be necessary to increase the dose of Kalcipos-D.
Hypercalcaemia may increase the toxicity of cardiac glycosides during treatment with calcium and vitamin D. Patients should be monitored with regard to electrocardiogram (ECG) and serum calcium levels.
The efficacy of levothyroxine can be reduced by the concurrent use of calcium, due to decreased levothyroxine absorption. Administration of calcium and levothyroxine should be separated by at least four hours.
If a bisphosphonate is used concomitantly, this preparation should be administered at least one hour before the intake of Kalcipos-D since gastrointestinal absorption may be reduced.
Calcium may also reduce absorption of sodium fluoride and iron salts, and such preparations should be administered at least three hours before the intake of Kalcipos-D.
Administration of strontium and calcium should be separated by at least 2 hours, as calcium may reduce the absorption of strontium.
Simultaneous treatment with orlistat, ion exchange resins such as cholestyramine or laxatives such as paraffin oil may reduce the gastrointestinal absorption of vitamin D.
Calcium carbonate may interfere with the absorption of concomitantly administered tetracycline preparations. For this reason, tetracycline preparations should be administered at least two hours before or four to six hours after oral intake of calcium.
The absorption of quinolone antibiotics may be impaired if administered concomitantly with calcium. Quinolone antibiotics should be taken two hours before or six hours after intake of calcium.
Oxalic acid (found in spinach and rhubarb) and phytic acid (found in whole cereals) may inhibit calcium absorption through formation of insoluble compounds with calcium ions. The patient should not take calcium products within two hours of eating foods high in oxalic acid and phytic acid.
During pregnancy the daily intake should not exceed 1500 mg calcium and 600 IU vitamin D. Kalcipos-D is not recommended during pregnancy. Studies in animals have shown reproductive toxicity of high doses of vitamin D (see 5.3). In pregnant women, overdoses of calcium and vitamin D should be avoided as permanent hypercalcaemia has been related to adverse effects on the developing foetus. Tablets can be used during pregnancy, in case of a calcium and vitamin D deficiency.
Kalcipos-D can be used during breast-feeding. Calcium and vitamin D3
pass into breast milk. This should be considered when giving additional vitamin D to the child.
Normal endogenous levels of calcium and vitamin D are not expected to have any adverse effects on fertility.
There are no data about the effect of this product on driving capacity. An effect is, however, unlikely.
Adverse reactions frequencies are defined as: uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) or not known (cannot be estimated from the available data)
Immune system disorders
Not known (cannot be estimated from the available data): Hypersensitivity reactions such as angioedema or laryngeal edema.
Metabolism and nutrition disorders
Uncommon: Hypercalcaemia and hypercalciuria.
Rare: Constipation, flatulence, nausea, abdominal pain, and diarrhoea.
Skin and subcutaneous disorders
Rare: Pruritus, rash and urticaria.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Overdose can lead to hypervitaminosis and hypercalcaemia. Symptoms of hypercalcaemia may include anorexia, thirst, nausea, vomiting, constipation, abdominal pain, muscle weakness, fatigue, mental disturbances, polydipsia, polyuria, bone pain, nephrocalcinosis, renal calculi and in severe cases, cardiac arrhythmias. Extreme hypercalcaemia may result in coma and death. Persistently high calcium levels may lead to irreversible renal damage and soft tissue calcification.
Treatment of hypercalcaemia: The treatment with calcium and vitamin D must be discontinued. Treatment with thiazide diuretics, lithium, vitamin A, vitamin D and cardiac glycosides must also be discontinued. Rehydration, and, according to severity, isolated or combined treatment with loop diuretics, bisphosphonates, calcitonin and corticosteroids. Serum electrolytes, renal function and diuresis must be monitored. In severe cases, ECG and CVP should be followed.
Pharmacotherapeutic group: Mineral supplements
Vitamin D increases the intestinal absorption of calcium.
Administration of calcium and vitamin D3
counteracts the increase of parathyroid hormone (PTH) which is caused by calcium deficiency and which cause increased bone resorption.
The amount of calcium absorbed through the gastrointestinal tract is approximately 30% of the swallowed dose.
Distribution and biotransformation:
99% of the calcium in the body is concentrated in the hard structure of bones and teeth. The remaining 1% is present in the intra- and extracellular fluids. About 50% of the total blood-calcium content is in the physiologically active ionised form with approximately 10% being complexed to citrate, phosphate or other anions, the remaining 40% being bound to proteins, principally albumin. The bioavailability of calcium can be slightly increased by concomitant intake of food.
Calcium is eliminated through faeces, urine and sweat. Renal excretion depends on glomerular filtration and calcium tubular reabsorption.
Vitamin D is easily absorbed in the small intestine.
Distribution and metabolism: Cholecalciferol and its metabolites circulate in the blood bound to a specific globulin. Cholecalciferol is converted in the liver by hydroxylation to the active form 25-hydroxycholecalciferol. It is then further converted in the kidneys to 1,25- dihydroxycholecalciferol. 1,25-dihydroxycholecalciferol is the metabolite responsible for increasing calcium absorption. Vitamin D which is not metabolised is stored in adipose and muscle tissues.
Vitamin D is excreted in faeces and urine.
At doses far higher than the human therapeutic range teratogenicity has been observed in animal studies. There is further no information of relevance to the safety assessment in addition to what is stated in other parts of the SPC.
Liquid spray dried glucose
Medium chain triglycerides
Starch sodium octenyl succinate (E 1450)
Shelf life: 3 years
Shelf life after first opening container: 6 months
Store in the original container, in order to protect from light. Keep container tightly closed in order to protect from moisture.
For storage conditions after first opening of medicinal product, see section 6.3
20, 30,40,50,60, 90, 100 and 180 chewable tablets in plastic containers of HDPE with screw caps made of HDPE.
Not all pack sizes may be marketed.
Meda Pharmaceuticals Ltd,
Takeley, Bishop's Stortford CM22 6PU
Date of first authorisation: 29 January 2010
Date of latest renewal: 22 December 2014